AdvaMed Releases Guidelines for Patient Data Best Practices
The Advanced Medical Technology Association has developed a set of principles for patient data access, which is intended to foster trust between med tech companies and their partners in healthcare systems. Adherence to these principles may also aid industry in its efforts to obtain more routine access to real-world evidence (RWE), a consideration of growing importance for the FDA.
The FDA’s Center for Devices and Radiological Health (CDRH) maintains a webpage for RWE, including an updated version of a 2017 guidance on the use of RWE to support regulatory decision-making. Section II of the AdvaMed guidelines states that implementation of these best practices will be helpful in the collection of RWE, which the FDA guidance states may be useful in reviews of premarket applications and for other purposes across the device life cycle.
AdvaMed states that these guidelines may reduce contracting and implementation delays in obtaining access to patient data, which may be de-identified or pseudo-anonymized. For the purposes of these guidelines, the term “data” may include patient-level data, administrative data, or product performance data.
AdvaMed’s digital health technology group states that these guidelines may help ensure that manufacturers are in compliance with U.S. federal and state law, including the Health Insurance Portability and Accountability Act (HIPAA). The guidelines recommend that manufacturers post a notice of privacy practices on the company’s website, which would describe how data is collected, used and protected. However, a firm’s partners in the health system would ordinarily be tasked with providing patients with disclosures as to the purposes for which their data will be used, including when the data is accessed by artificial intelligence (AI) software.
Any agreements undertaken between manufacturers and health system entities should describe the duration of data retention, which must be in accordance with both federal and state law. AdvaMed advises member companies that data that cross national boundaries may come with compliance requirements that are distinct from the requirements in the U.S. or in U.S. states.
Section 4 of the guidelines addresses the use of AI and advanced analytics on data, recommending that manufacturers install mechanisms of oversight to ensure compliance with federal and state law. One concern in this context is the risk of bias, but AdvaMed also recommends that manufacturers evaluate their AI and machine-learning software across the product life cycle to ensure the algorithm continues to perform reliably.
AdvaMed advises that some jurisdictions are in the process of forming AI governance requirements, which a manufacturer should take into account when developing internal compliance programs. This is particularly the case for technologies that may remain on the market for an extended period of years. AdvaMed pointed to its October 2024 document outlining[KN1] the principles for artificial intelligence in medical and digital health technologies for additional insight into these questions.
The AdvaMed guidelines provide several recommendations regarding the de-identification of patient data, a key compliance consideration for medical device manufacturers and healthcare systems alike. The guidelines recommend that manufacturers make use of a series of controls to reduce the risk of re-identification of patient data, including both technological and contractual measures.
A manufacturer should also consider how technological evolution might alter the risk of re-identification, which may force a later adjustment of the controls used to suppress such risks. AdvaMed states that coded data might also retain a re-identification risk despite the assumption that coded data formats significantly reduce the risk of re-identification. AdvaMed said these guidelines are voluntary.
How Medmarc Can Help
Life sciences and medical technology companies face complex and evolving risks throughout the product lifecycle. Medmarc provides specialized life sciences insurance, medical device insurance, products liability coverage, and risk management expertise to address the unique exposures of the industry. From emerging technologies and clinical trials to products on the market, Medmarc combines decades of life sciences experience with specialized industry knowledge and insurance solutions.
Explore Medmarc's insurance solutions to learn more about our capabilities, and talk with your insurance broker about your organization’s evolving risks and insurance considerations.
Phone: 888-633-6272
Copyright © 2026 - Medmarc
Related Articles
Medmarc is a proud member of TDC Specialty. TDC Specialty is the marketing name for the specialty insurance operations and services of The Doctors Company and its subsidiaries and affiliated companies, including TDC Specialty Underwriters, Inc., TDC Specialty Insurance Company, TDC National Assurance Company, Healthcare Risk Advisors, Inc., Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, and Medmarc Casualty Insurance Company. All products and services are written or provided by subsidiaries or affiliates of The Doctors Company. The Doctors Company does not underwrite excess and surplus lines insurance. Certain coverages may be provided through surplus lines insurance subsidiaries of The Doctors Company through licensed surplus lines brokers. Coverages may be underwritten by TDC Specialty Insurance Company, TDC National Assurance Company, Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, or Medmarc Casualty Insurance Company. Product summaries are for informational purposes only. Coverage is subject to the language of the policy as actually issued. Coverage, policy terms, and availability may vary by state.
TDC Specialty Underwriters, Inc., is based and domiciled in Connecticut; in California d/b/a Insurance City Solutions (license #0L85833) and in New York, d/b/a TDC Specialty Underwriters Services. Healthcare Risk Advisors, Inc., is based and domiciled in New York.
